Bausch Health hires Jonathan Sadeh to lead research and development

In Laval, Quebec on December 2, 2024, Bausch Health Companies Inc. announced the hiring of Jonathan Sadeh as the new Executive Vice President, Chief Medical Officer, and Head of Research and Development. This strategic appointment is aimed at strengthening the company's commitment to innovation and excellence in healthcare. Jonathan Sadeh brings over 20 years of experience in clinical research and drug development, having worked in significant roles at major pharmaceutical companies including Bristol-Meyers Squibb, Sanofi, Astra-Zeneca, and Schering-Plough. His experience spans multiple successful drug approvals, particularly in the fields of dermatology and gastroenterology, showcasing his ability to foster innovation in the pharmaceutical industry. As the new R&D head, Sadeh will oversee the entire research and development process. He is expected to align the R&D teams with the company's overall mission of enhancing health outcomes and enriching lives. Sadeh’s educational background includes a master’s degree in clinical research from Harvard Medical School and a medical degree from Mount Sinai School of Medicine, which bolsters his capacity to lead Bausch Health's R&D efforts effectively. The appointment has been welcomed by Bausch Health's CEO, Thomas J. Appio, who noted that Jonathan's innovative vision and extensive expertise would significantly contribute to the company's pipeline development and future advancements in healthcare. His ability to drive growth and innovation aligns well with Bausch Health’s strategic goals, especially as the company navigates an ever-evolving pharmaceutical landscape. Overall, the hiring of Jonathan Sadeh represents a crucial step for Bausch Health in its quest for breakthroughs in drug development and improved health outcomes, signaling the company's readiness to take on new challenges in the pharmaceutical sector and maintain its commitment to health and wellness.